The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Tyck till om SwePub Sök här!

Sökning: WFRF:(Brambilla Elisabeth) > The Promises and Ch...

The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker : A Perspective from the International Association for the Study of Lung Cancer Pathology Committee

Sholl, Lynette (författare): Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.;Harvard Med Sch, 75 Francis St, Boston, MA 02115 USA.

Hirsch, Fred R. (författare): Tisch Canc Inst, Ctr Thorac Oncol, New York, NY USA.;Mt Sinai Hlth Syst, Icahn Sch Med, New York, NY USA.

Hwang, David (författare): Sunnybrook Hlth Sci Ctr, Dept Lab Med & Mol Diagnost, Toronto, ON, Canada.

visa fler...

Botling, Johan (författare): Uppsala universitet,Klinisk och experimentell patologi,Science for Life Laboratory, SciLifeLab,Johan Botling

Lopez-Rios, Fernando (författare): HM Hosp, Pathol Lab Dianas Terapeut, Madrid, Spain.

Bubendorf, Lukas (författare): Univ Hosp Basel, Inst Pathol, Basel, Switzerland.

Mino-Kenudson, Mari (författare): Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.

Roden, Anja C. (författare): Mayo Clin, Dept Pathol, Rochester, MN USA.

Beasley, Mary Beth (författare): Mt Sinai Hlth Syst, Icahn Sch Med, New York, NY USA.

Borczuk, Alain (författare): Weill Cornell Med, Dept Pathol, New York, NY USA.

Brambilla, Elisabeth (författare): Univ Grenoble Alpes, Grenoble, France.

Chen, Gang (författare): Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China.

Chou, Teh-Ying (författare): Taipei Vet Gen Hosp, Taipei, Taiwan.

Chung, Jin-Haeng (författare): Seoul Natl Univ, Bundang Hosp, Seoul, South Korea.

Cooper, Wendy A. (författare): Royal Prince Alfred Hosp, Camperdown, NSW, Australia.

Dacic, Sanja (författare): Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA USA.

Lantuejoul, Sylvie (författare): Univ Grenoble Alpes, Grenoble, France.;Ctr Leon Berard Unicancer, Lyon, France.

Jain, Deepali (författare): All India Inst Med Sci, New Delhi, India.

Lin, Dongmei (författare): Peking Univ Canc Hosp & Inst, Dept Pathol, Beijing, Peoples R China.

Minami, Yuko (författare): Ibarakihigashi Natl Hosp, Tokai, Ibaraki, Japan.

Moreira, Andre (författare): Weill Cornell Med, Dept Pathol, New York, NY USA.

Nicholson, Andrew G. (författare): Royal Brompton & Harefield NHS Fdn Trust, London, England.;Imperial Coll, Natl Heart & Lung Inst, London, England.

Noguchi, Masayuki (författare): Univ Tsukuba, Tsukuba, Ibaraki, Japan.

Papotti, Mauro (författare): Univ Turin, Dept Oncol, Turin, Italy.

Pelosi, Giuseppe (författare): Univ Milan, Milan, Italy.;Ist Ricovero & Cura Carattere Sci MultiMed, Dept Oncol & Hematooncol, Milan, Italy.

Poleri, Claudia (författare): Oggice Pathol Consultants, Buenos Aires, DF, Argentina.

Rekhtman, Natasha (författare): Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA.

Tsao, Ming-Sound (författare): Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada.

Thunnissen, Erik (författare): Vrije Univ Amsterdam, Med Ctr, Dept Pathol, Amsterdam, Netherlands.

Travis, William (författare): Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA.

Yatabe, Yasushi (författare): Natl Canc Ctr, Tokyo, Japan.

Yoshida, Akihiko (författare): Natl Canc Ctr, Tokyo, Japan.

Daigneault, Jillian B. (författare): Int Assoc Study Lung Canc, Aurora, CT USA.

Zehir, Ahmet (författare): Oggice Pathol Consultants, Buenos Aires, DF, Argentina.

Peters, Solange (författare): Lausanne Univ, Ctr Hosp Univ Vaudois, Oncol Dept, Lausanne, Switzerland.

Wistuba, Ignacio I. (författare): Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.

Kerr, Keith M. (författare): Aberdffn Royal Infirm, Dept Pathol, Aberdffn, Scotland.

Longshore, John W. (författare): Atrium Hlth, Carolinas Pathol Grp, Charlotte, NC USA.

visa färre...

Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA;Harvard Med Sch, 75 Francis St, Boston, MA 02115 USA. Tisch Canc Inst, Ctr Thorac Oncol, New York, NY USA.;Mt Sinai Hlth Syst, Icahn Sch Med, New York, NY USA. (creator_code:org_t)

ELSEVIER SCIENCE INC, 2020
2020
Engelska.
Ingår i: Journal of Thoracic Oncology. - : ELSEVIER SCIENCE INC. - 1556-0864 .- 1556-1380. ; 15:9, s. 1409-1424

Relaterad länk:: https://doi.org/10.1...; visa fler...; https://urn.kb.se/re...; https://doi.org/10.1...; visa färre...

Forskningsöversikt (refereegranskat)

Abstract Ämnesord

Stäng

Immune checkpoint inhibitor (ICI) therapies have revolutionized the management of patients with NSCLC and have led to unprecedented improvements in response rates and survival in a subset of patients with this fatal disease. However, the available therapies work only for a minority of patients, are associated with substantial societal cost, and may lead to considerable immune-related adverse events. Therefore, patient selection must be optimized through the use of relevant biomarkers. Programmed death-ligand 1 protein expression by immunohistochemistry is widely used today for the selection of programmed cell death protein 1 inhibitor therapy in patients with NSCLC; however, this approach lacks robust sensitivity and specificity for predicting response. Tumor mutation burden (TMB), or the number of somatic mutations derived from next-generation sequencing techniques, has been widely explored as an alternative or complementary biomarker for response to ICIs. In theory, a higher TMB increases the probability of tumor neoantigen production and therefore, the likelihood of immune recognition and tumor cell killing. Although TMB alone is a simplistic surrogate of this complex interplay, it is a quantitative variable that can be relatively readily measured using currently available sequencing techniques. A large number of clinical trials and retrospective analyses, employing both tumor and blood-based sequencing tools, have evaluated the performance of TMB as a predictive biomarker, and in many cases reveal a correlation between high TMB and ICI response rates and progression-free survival. Many challenges remain before the implementation of TMB as a biomarker in clinical practice. These include the following: (1) identification of therapies whose response is best informed by TMB status; (2) robust definition of a predictive TMB cut point; (3) acceptable sequencing panel size and design; and (4) the need for robust technical and informatic rigor to generate precise and accurate TMB measurements across different laboratories. Finally, effective prediction of response to ICI therapy will likely require integration of TMB with a host of other potential biomarkers, including tumor genomic driver alterations, tumor-immune milieu, and other features of the host immune system. This perspective piece will review the current clinical evidence for TMB as a biomarker and address the technical sequencing considerations and ongoing challenges in the use of TMB in routine practice. (c) 2020 Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Klinisk laboratoriemedicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Clinical Laboratory Medicine (hsv//eng)

Nyckelord

TMB
NSCLC
Immunotherapy
Biomarker
PD-L1
Patologi
Pathology

Publikations- och innehållstyp

ref (ämneskategori)
for (ämneskategori)

Hitta via bibliotek

Journal of Thoracic Oncology (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Cancer och onkol ...

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Klinisk laborato ...

Artiklar i publikationen: Journal of Thora ...

Av lärosätet: Uppsala universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se